Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HNF4A | P41235 | 1/20 | 0.41 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9223952 | 0.90 | HNF4A (0.44) | MAPTKDM4EALDH1A1CYP1A2MAPK1 | |
| SCHEMBL27633472 | 0.88 | MAPT (0.48) | MAPTALDH1A1HPGDHNF4APADI4 | |
| SCHEMBL7791409 | 0.84 | MAPT (0.46) | MAPTALDH1A1PADI4NOTUMBCAT2 | |
| SCHEMBL17604415 | 0.84 | BCAT2 (0.50) | MAPTMAPK1CYP2C19BCAT2PRKAA1 | |
| SCHEMBL1925378 | 0.82 | MAPT (0.41) | MAPTKDM4EALDH1A1CASP1CYP2C19 | |
| SCHEMBL15511168 | 0.82 | AURKA (0.53) | MAPTKDM4EALDH1A1NOTUMIKBKB | |
| SCHEMBL20568646 | 0.81 | KMO (0.47) | MAPTKDM4EALDH1A1PIN1HPGD | |
| SCHEMBL16007019 | 0.80 | HTT (0.54) | MAPTALDH1A1HPGDPADI4FGFR1 | |
| SCHEMBL20568173 | 0.77 | RXRA (0.46) | KDM4EALDH1A1HPGD | |
| SCHEMBL7384701 | 0.77 | XDH (0.50) | PIN1IKBKBCHUKCLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117820191-B | Diphenylamine compound and preparation method, application and pharmaceutical composition thereof | FUDAN UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-117820191-A | Diphenylamine compound and preparation method, application and pharmaceutical composition thereof | 复旦大学 | 2024-04-05 | — | — | CN | disclosed |
| US-11413272-B2 | Inhibitors of metallo-beta-lactamases | OXFORD UNIVERSITY INNOVATION LIMITED | 2022-08-16 | — | — | US | disclosed |
| EP-3630728-B1 | INHIBITORS OF METALLO-BETA-LACTAMASES | UNIV OXFORD INNOVATION LTD (GB) | 2022-07-27 | — | — | EP | disclosed |
| US-20210137884-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| US-20210137884-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3630728-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | Oxford University Innovation Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215799-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
| US-8426453-B2 | Treatment of a stomach or small intestine ulcer with 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid | ASTELLAS PHARMA INC. (JP) | 2013-04-23 | — | — | US | disclosed |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| EP-1992361-B1 | Remedy or preventive for digestive ulcer | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8067446-B2 | Methods for treating an ulcer of the small intestine and stomach | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20110281919-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| US-7608594-B2 | Novobiocin analogues as anticancer agents | UNIVERSITY OF KANSAS (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
| CN-101389352-A | Agent for treating or preventing digestive ulcer | ASTELLAS PHARMA INC (JP) | 2009-03-18 | — | — | CN | disclosed |
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1992361-A1 | REMEDY OR PREVENTIVE FOR DIGESTIVE ULCER | Astellas Pharma Inc. (JP) | 2008-11-19 | — | — | EP | disclosed |
| US-20050014765-A1 | Aryl-heteroaromatic products, compositions comprising them and use | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
| EP-0628042-A1 | SEROTONINERGIC ERGOLINE DERIVATIVES | PHARMACIA & UPJOHN S.p.A. (IT) | 1994-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11413272-B2 | Inhibitors of metallo-beta-lactamases | MGAM, GAA, ALPI | MAPT 2741/4885KDM4E 2289/4885ALDH1A1 210/4885 |
| US-20050014765-A1 | Aryl-heteroaromatic products, compositions comprising them and use | AHR, ARNT, MYC | MAPT 3583/4885KDM4E 1246/4885ALDH1A1 240/4885 |
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | XDH, PEPD, HPN | MAPT 4428/4885KDM4E 4662/4885ALDH1A1 959/4885 |
| US-20210137884-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | MGAM, GAA, ALPI | MAPT 2741/4885KDM4E 2289/4885ALDH1A1 210/4885 |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | HSP90AB1, HSP90B1, HSP90AB2P | MAPT 1221/4885KDM4E 4217/4885ALDH1A1 3407/4885 |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | HSP90AB1, HSP90AB2P, HSP90B1 | MAPT 3883/4885KDM4E 2965/4885ALDH1A1 3066/4885 |
| US-20110281919-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | XDH, PEPD, HPN | MAPT 4428/4885KDM4E 4662/4885ALDH1A1 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.